Title
T cells in the control of organ-specific autoimmunity

Permalink
https://escholarship.org/uc/item/7ms4s2m7

Journal
Journal of Clinical Investigation, 125(6)

ISSN
0021-9738

Authors
Bluestone, JA
Bour-Jordan, H
Cheng, M
et al.

Publication Date
2015-01-01

DOI
10.1172/JCI78089

Peer reviewed
**T cells in the control of organ-specific autoimmunity**

Jeffrey A. Bluestone, Hélène Bour-Jordan, Mickie Cheng, and Mark Anderson

Diabetes Center, UCSF, San Francisco, California, USA.

---

**Introduction**

Genetic predisposition for most autoimmune disorders is polygenic and conferred by shared as well as disease-specific alleles. Genome-wide association studies have identified dozens of genetic variants associated with autoimmunity (1). The MHC loci confer the highest genetic risk in many autoimmune diseases, pointing to a critical role for antigen T cell interactions in disease pathogenesis. Additionally, many of the shared variants have pleiotropic effects on pathways that are important for conventional T cells (Tconv) but are also critical for the homeostasis and/or function of Tregs, such as IL-2, CD25, cytotoxic T lymphocyte–associated protein 4 (CTLA4), and protein tyrosine phosphatase, non-receptor type 22 (2–4). Conversely, disease-specific associations implicate variants for genes either encoding major autoantigens or that are involved in their generation (5, 6). Although beyond the scope of this Review, rare genetic variants have also been critically informative about the role of innate immunity or other arms of the immune system in systemic autoimmune diseases such as lupus (7), which are beyond the scope of this discussion. Taken together, genetics studies point to the central role of pathways involved in thymic T cell education and peripheral immunoregulation by Tregs for the control of autoimmune diseases.

Immune tolerance stems from the control of autoreactive T cells both in the thymus and the periphery, owing to mechanisms known as central and peripheral tolerance, respectively. Central tolerance eliminates potentially autoreactive lymphocytes that develop in the thymus by subjecting thymocytes with high affinity for self antigens to either clonal deletion (negative selection) or selection into the Treg lineage. Many autoreactive T cells escape this checkpoint and can be found in the peripheral blood of healthy individuals; however, these self-reactive cells are not sufficient to induce autoimmunity due to additional controls by peripheral tolerance mechanisms (8–11). Peripheral tolerance is achieved through T cell–intrinsic mechanisms that lead to clonal deletion, anergy, or immunological ignorance as well as extrinsic control by specialized populations of suppressor cells that regulate potentially harmful responses of autoreactive T and B cells (12, 13). First among these are CD4+CD25 Foxp3+ Tregs, a T cell population that is essential for extrinsic control of peripheral tolerance (14, 15).

Tregs play a fundamental role in inhibiting self-reactivity and maintaining immune tolerance (16). Several types of Tregs have been described, including Foxp3+ IL-10–dependent Tr1 cells, LAP+ TGF-β–dependent Th3 cells, and CD8+ Tregs; however, in this Review we focus on Tregs that express the transcription factor Foxp3, a “master regulator” of this Treg lineage that is crucial for their homeostasis and function. Loss-of-function mutations in the FOXP3 gene are responsible for immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, which is characterized by widespread and often fatal autoimmunity shortly after birth (17). Similarly, mice deficient in Foxp3 completely lack Tregs and rapidly develop lethal multi-organ autoimmunity (18, 19). The requirement for Foxp3 expression in Tregs is quantitative in nature and lifelong, as illustrated by the development of lymphoproliferative disease within days of acute depletion of Foxp3+ Tregs in adult mice (20, 21).

**Central tolerance as a key checkpoint**

The generation of an extremely diverse T cell repertoire in the thymus through stochastic gene rearrangement of the TCR is a powerful weapon in our immunity against pathogens. At the same time, collateral damage can occur when autoreactive T cells...
are generated through this stochastic process, which is a critical challenge in immune tolerance. A key mechanism in maintaining tolerance occurs in the thymic medulla, where self antigens are presented to developing T cells by both medullary thymic epithelial cells (mTECs) and resident bone marrow–derived APCs. mTECs have the unusual property of expressing a wide array of tissue-specific self antigens (TSAs), which shape the developing T cell repertoire. This ectopic antigen expression relies on the autoimmune regulator (Aire) gene (22–24); patients with defects in Aire succumb to an autoimmune syndrome termed autoimmune polyglandular syndrome type 1, which is characterized by multi-organ immune infiltrates and autoantibodies (25). Tolerance against TSAs, through clonal deletion and Treg development in organ immune infiltrates and autoantibodies (25). Tolerance occurs in the thymic medulla, where self antigens are generated through this stochastic process, which is a critical mechanism to help ensure the continuous display of diverse self antigens. While the human thymus undergoes involution with age, increases in thymopoiesis can be seen following immunodepletion (e.g., with HIV or cytotoxic therapies), and new thymic emigrants can be observed in normal individuals even late in life (36, 37), suggesting a contribution for thymic function throughout life. This implies that approaches could be utilized to either enhance or block the thymic negative selection process to improve or break self-tolerance. Notably, these findings also suggest that patients treated with denosumab (an anti-RANKL mAb) should be closely examined for autoimmunity complications.

**Self-antigen recognition by autoreactive T cells**

A growing body of work suggests that many autoreactive T cells have unusual binding properties for their cognate MHC-peptide ligands. Autoreactive T cells with unusual TCR topologies may escape thymic deletion due to aberrant/reduced binding to the MHC that is insufficient to trigger apoptosis (38). Structural analyses of TCRs from patients with MS and T1D have revealed this property of autoreactive TCRs specific for disease-specific self-peptides, such as myelin basic protein and insulin (39, 40). Additionally, the processing and presentation of peptides plays a large role in shaping the T cell repertoire during thymic education. Recent work from Kappler and colleagues has determined that insulin-specific CD4+ T cells in the NOD mouse model have a propensity to react to a peptide of insulin that sits in the MHC groove in the suboptimal of three binding registers (41, 42). The affinity of this 15–amino acid peptide derived from the insulin B chain (Ins9–23) for the NOD mouse MHC class II allele, I-Ag7, is relatively weak. An I-Ag7/Ins9–23–optimized peptide tetramer locked into the least favored register reacts with multiple T cells enriched in the islets of prediabetic mice. This work has now been translated to human subjects with T1D that have DQ8-restricted insulin-specific T cells (43). Recent work from the Unanue group has suggested that this type of peptide-MHC complex may involve insulin peptide–loading events that uniquely occur in pancreatic islets but not in normal APCs (44, 45). In support of this hypothesis, when whole insulin protein is provided to normal APCs, many Ins9–23–reactive T cells do not respond; however, they can respond when peptide is presented to them or antigen is provided from whole pancreatic islets (44, 45). These studies suggest that T cells that recognize insulin peptides in higher-affinity binding registers are efficiently deleted in the thymus, perhaps in an Aire-dependent manner.

In addition to the example of insulin, there are also documented cases of myelin epitopes and other islet antigen epitopes, in which the antigenic peptide recognized by autoreactive T cells is sitting in the MHC binding groove in an unusual fashion (46–49). Moreover, a recent study in humans suggests that epitope presentation within the target tissue may affect the response of pathogenic CD8+ T cells. Indeed, a 9-mer peptide of glutamate carboxylase 65 is not generated by the endogenous pathway of antigen processing in islets in normal conditions but is recognized by some autoreactive CD8+ T cells and forms complexes with MHC class I molecules that are more stable than those formed with the longer, naturally presented 10-mer peptide (50). Likewise, the ability of certain MHC types to accommodate posttranslationally modified peptides may be part of the basis for T cell autoreactivity in RA and celiac disease (51, 52). A potential key commonality to these findings is the strong imposition of thymic tolerance on the immune repertoire and autoreactive T cell specificities that often involve a mismatch with the self antigens displayed in the thymus.

**Thymic Treg selection**

In addition to its role in promoting deletion of autoreactive T cells, the thymus can also help to prevent autoimmunity by promoting the positive selection of Foxp3+ Tregs (Figure 1). During thymic selection the small subpopulation of CD4+ T cells that express Foxp3 is selected on high-affinity peptides in a selective thymic niche (53). Although multiple APC populations in the thymus likely contribute to Treg selection (54), studies have suggested a potential role for Aire in this process (55–57). Using a limited T cell repertoire system in mice, the Hsieh group sequenced a large number of TCR sequences in the presence or absence of Aire and of individual APC populations in the thymus (55). Aire expression controlled selective expression of certain Treg sequences through the direct expression of self antigens by mTECs. However, a significant fraction of Tregs develop in an Aire-independent manner, which explains in part why Treg frequencies are relatively normal in Aire-deficient mice (58). Looking forward, it will be interesting to determine the actual antigen specificities of the Treg TCRs that
than one of deletion. Aire dependent and why these cells adopt the Treg fate rather than in inflammatory bowel disease (IBD) (59–61). Additionally, the evolution of several autoimmune diseases mirrors qualitative changes that occur over time in autoreactive effector T cells (Teffs) and that affect their ability to be controlled by Tregs (62–64). Thus, the development of autoimmune defects reflects alterations in both pathogenic T cells and Tregs, underlining the fact that a proper balance of Teffs and Tregs is critical to achieve and maintain peripheral tolerance (65). In humans, defects in the number, phenotype, and/or function of Tregs have been described in many autoimmune diseases, including T1D and MS (15, 66, 67). Defective STAT5 phosphorylation upon IL-2 signaling, which has been observed in patients with T1D and MS, may alter Foxp3 expression and contribute to the loss of peripheral tolerance and development of autoimmunity (refs. 68–70 and Figure 1). Of note, it has sometimes been challenging to reach a consensus on the nature and extent of Treg defects in T1D and other autoimmune diseases because of conflicting reports on the number of circulating Tregs and their in vitro suppressive ability in T1D patients compared with healthy controls (15, 71–74). These discrepancies may be related in part to the absence of a unique Treg lineage marker, the lack of in vitro assays that faithfully reflect in vivo suppressive function (75), and, in most cases, the fact that the only cells available from human subjects are PBMCs, which may not always be appropriate to reveal tissue-specific Treg defects (76).

Immunoregulation by distinct subsets of Tregs

Tregs develop both as a specialized subset in the thymus (tTregs) as described above (77, 78) and as a consequence of Foxp3 induction in Tconv on exposure to antigens in the periphery (pTregs), either in steady state or following tolerogenic treatments (79–83). The developmental pathways of both tTregs and pTregs share requirements for TCR stimulation and IL-2 signaling. TGF-β and retinoic acid are critical for the generation of pTregs and are likely involved in the preferential induction of pTregs in mucosal surfaces, notably the intestinal mucosa (84–87). Commensal bacteria are instrumental in the generation of large numbers of colonic pTregs, as bacteria in the gut provide a TGF-β-rich environment and produce metabolites that induce epigenetic modifications that promote differentiation of Tconv into pTregs (88–91). It is unclear whether a specific tissue niche is related to the unique features and requirements of the gut or whether it results from tissue-specific mechanisms for maintaining peripheral tolerance in distinct tissues.

While both tTregs and pTregs can efficiently suppress Tconv responses in vitro, their respective roles in peripheral tolerance remain controversial (92). Accumulating evidence suggests that both tTregs and pTregs are required to prevent autoimmunity under certain inflammatory conditions (93–95). A lack of pTregs has been associated with inflammation at mucosal sites, even with a normal tTreg compartment (94, 95). Conversely, pTregs are capable of controlling islet-specific but not CNS-specific autoreactive T cells, while tTregs can control both (96). This raises the possibility that pTregs and tTregs may play specialized and complementary roles in peripheral tolerance (81). The TCR repertoire of Tregs and Tconv is largely distinct and overlaps primarily between Tregs and autoreactive Tconv (77, 97–99). We further hypothesize that tTregs primarily maintain immune homeostasis by continuously controlling T cell responses against shared and ubiquitous self antigens, whereas pTregs are generated locally after recognition of TSAs and, due to their limited stability, transiently regulate autoreactive responses in tissues (Figure 2). The
function of pTregs in the inflammatory setting may contribute to autoimmunity (Figure 2).

Stability of Tregs

Whereas the majority of Tregs remain Foxp3+, a subset may become unstable and lose Foxp3 expression in inflammatory or lymphopenic conditions (102, 103). For example, CD4+ Foxp3+ Tregs can be reprogrammed to produce IL-17 and IFN-γ in inflammatory environments in mice and humans (76, 104, 105). These “ex-Foxp3” cells can mediate autoimmunity in mouse models of autoimmune diabetes and arthritis (102, 106). Of note, the stability of Tregs has been a controversial topic, as other studies concluded that fully differentiated Tregs were stable while ex-Foxp3 cells were derived from loosely committed Tregs; however, these studies were not performed in the setting of autoimmunity (107, 108). Conversely, in the EAE model of MS, loss of Foxp3 and Treg instability were observed in bona fide Tregs and occurred predominantly in autoreactive Tregs in the context of self antigen-driven activation and inflammation (109). Moreover, similar phenomena of Treg plasticity and instability have been described in humans with T1D, RA, and MS and correspond to distinct molecular stages with discrete epigenetic and gene expression signatures (106, 110, 111).

Figure 2. Model for self-peptide presentation in shaping T cell function and development of autoimmunity. Mounting data support a key role for self-antigen presentation in T cell selection and autoimmunity. Left: In the thymus, CD4+ T cells with high affinity for self antigens undergo apoptosis (Tconv A) (i), while Tconv B escape negative selection (ii) due to low affinity for “classical” stable peptide MHC (pMHC) complexes that are formed by processing and loading of self-proteins onto MHC class II molecules in late endosomes (iv). Tregs arise from thymocytes that interact with self pMHC complexes with a high affinity insufficient to trigger negative selection (iii) and recognize self-peptides both from homeostasis-related tissue nonspecific antigens (pink rectangles) and from tissue-restricted antigens (yellow rectangles), expressed under the control of Aire in mTECs (iv). Right: In the periphery, positively selected Tregs and Tconvs encounter pMHC complexes that only partially overlap with those presented in the thymus (v). Unstable and/or tissue-specific pMHC complexes (v) may arise when extracellular self-peptides bypass classical processing to associate with MHC class II in early endosomes (yellow triangles). Thus, tTregs recognizing homeostasis antigens can be activated in the periphery (vi), whereas tTregs selected on classical pMHC complexes in the thymus cannot recognize the “peculiar” pMHC complexes uniquely generated in the periphery from the same tissue-restricted antigen (vii). These peculiar pMHC complexes can activate autoreactive cells that escaped negative selection (Tconv B) (viii) as well as pTregs generated in the periphery (ix). Thus, the limited diversity and frequency of tTregs in the tissue, combined with reduced stability and efficacy of pTregs in inflamed tissues, contributes to failure of local immunoregulation of autoreactive Tconv cells and resultant autoimmunity.
Autoimmune diseases result from an imbalance of pathogenic autoreactive Tconv cells and protective Tregs. Many immunotherapies for autoimmune diseases share a common goal of restoring immune tolerance but employ different strategies to skew the balance of immune responses toward dominant Treg-mediated regulation. Some systemic therapies, such as ATG or alefacept, reset the balance by inducing a massive but selective deletion of Tconv, including autoreactive T cells. Conversely, more recent approaches such as low-dose IL-2 or Treg cellular therapy aim at boosting the number and/or function of Tregs to a point where they are able to control autoreactive T cells. While both types of approaches have been successful in animal models and sporadically in humans, these monotherapies have thus far been largely ineffective at permanently curing autoimmune diseases. This has led to the notion that combination therapies that both eliminate autoreactive T cells and repair Treg defects may be necessary to sufficiently shift the immune scale toward regulation and durably reestablish tolerance.

Mechanistically, the primary prerequisite for the maintenance of the Treg population is stable Foxp3 expression (20, 112). The requirements for Foxp3 expression in Tregs include signaling through co-stimulatory and cytokine receptors (113–116). TCR/CD28 and IL-2R signaling are not only required for Treg development and homeostasis but are critical for their suppressive function (117, 118). In particular, signaling through IL-2R is critical for maintaining Foxp3 expression and Treg homeostasis (119). A Foxp3 intronic element known as the conserved noncoding sequence 2 (CNS2; also referred to as Treg-specific demethylated region) is highly demethylated in Tregs but completely methylated in other T cell lineages (120–122). CNS2 is important to stabilize Foxp3 expression upon Treg stimulation and division in inflammatory environments or conditions of limited IL-2 (123, 124). Importantly, CNS2 ensures stable inheritance of Foxp3 expression and maintains Treg lineage identity by acting as a sensor of TCR/NFAT and IL-2/STAT5 signals.

Finally, the issues of Treg plasticity and stability have important implications in the context of therapeutic approaches in autoimmune diseases. The potential instability of a fraction of Tregs may result in acceleration of disease after Treg-based therapy, which raises concerns about application of this approach to diseases such as MS, in which the continued destruction of vital tissue might lead to increased morbidity. Thus, an important goal for Treg-based therapy as well as therapies designed to improve Treg-mediated suppression will be to generate an environment that may alter the Treg transcriptome and possibly favor the stability of the Treg lineage.

Therapeutic strategies to restore tolerance
Many therapeutic approaches are aimed at recalibrating pathogenic/regulatory immune pathways to restore tolerance without compromising anti-pathogen defenses (Figure 3). To date, few immunotherapies have achieved immune tolerance, i.e., non-responsiveness to self antigens, without continuous immunosuppression. Coupled with the difficulty in designing effective clinical trials or testing of unlicensed combination therapies in patients, many barriers remain in realizing clinical tolerance induction and merit more critical discussion in the future. Below, we discuss the strides in the last decade that are leading to development of novel strategies aimed at restoring tolerance (125).

Systemic, nonspecific immunotherapies primarily targeting pathogenic autoreactive Teffs. Immunomodulatory therapies that target autoreactive Teffs are designed to work in part by deleting pathogenic cells, with the goal of “resetting” the immune system toward a more balanced homeostasis (126). Given that Tregs work in a dominant manner through bystander suppression and induce “infectious tolerance” (127), many immunotherapies currently under development target Treg defects identified in preclinical studies, with the goal of restoring Treg function (15, 128). Anti-thymocyte globulin (ATG) has shown promising results in NOD mice and a small clinical trial in patients with TID (129, 130) with tolerogenic potential suggested by its favorable effect on the Treg compartment in mice and humans (130–132). Recent phase II trials in patients with new-onset T1D showed no clear benefit for ATG monotherapy (133); however, a combination of low-dose ATG and G-CSF tended to preserve β cell function at 12 months following initiation of therapy (134). The disappointing outcome of ATG monotherapy may be due to ineffectual depletion of effector memory T cells, which are particularly resistant to deletion or suppression (135, 136), and suggests that eliminating these cells will be required for successful approaches. Similarly, targeting of CD52 by alemtuzumab, recently approved for relapsing-remitting MS, causes depletion of T and B cells, with subsequent repopulation through preferential homeostatic...
proliferation of pTregs and effector memory T cells (137–139). This selective expansion of T cell subsets may account for both the drug’s efficacy and the high rate of other autoimmune conditions seen in up to one-third of treated patients (140). Likewise, CD2 is expressed on almost all human T cells but is most highly expressed in memory and pathogenic Teffs in autoimmunity (141, 142). Treatment of psoriasis patients with a CD2 ligand-specific Fc fusion protein (alefacept) resulted in sustained remissions even after drug discontinuation in some patients (143, 144). Mechanistically, alefacept preferentially depletes effector memory T cells without eliminating Tregs (141, 145). Recently, treatment of TID with alefacept has shown promise, with some evidence of efficacy in a phase II clinical trial (146). Treatment with Fc receptor non-binding anti-CD3 mAbs teplizumab or otelixizumab in patients with new-onset TID preserved β cell function for up to two years; however, neither mAb ultimately prevented the destruction of the remaining β cells (147–150). The mechanisms of action of anti-CD3 mAbs remain unclear but include the selective depletion of activated T cells and induction or preferential retention of cells with regulatory properties (151–155).

Antigen-specific tolerogenic therapies are expected to be safer than nonspecific strategies due to a lower risk of global immunosuppression (125). Antigen therapy has successfully prevented or reversed autoimmune diseases in the NOD and EAE mouse models (156–159), indicating that targeting responses against one or a few self antigens can thwart polyclonal autoimmune responses. Enrichment in Tregs has been observed after antigen immunotherapy in patients with RA and TID (160–163). Administration of antigen-coupled ethylene carbodiimide–fixed cells (as well as, more recently, antigen-coated beads) has been extremely effective at restoring tolerance in NOD mice and EAE (164–167). Additionally, a recent phase I clinical trial in MS showed that this approach reduced myelin-specific autoreactive T cell responses in humans (168). Finally, recent studies in TID have focused on oral antigen delivery to promote tolerance due to postulated Treg induction and clonal anergy/deletional mechanisms (169). Based on a reduction of diabetes incidence in a small set of higher-risk individuals (170), a large-scale study of oral insulin for TID prevention is currently ongoing (ClinicalTrials.gov identifier NCT00419562).

**Immunotherapies aimed at restoring the control of autoimmune responses by Tregs.** The central role of IL-2 in Treg homeostasis and function has led to therapeutic strategies that aim to improve IL-2 signaling in Tregs (171). In NOD and EAE mouse models, treatment with low-dose IL-2 restored high levels of Foxp3 and CD25 expression, improved the stability of Tregs, and prevented or restored the development of autoimmunity (76, 109, 172). Administration of low-dose IL-2 in new-onset TID patients did not alter glucose metabolism but did induce a dose-dependent increase in the frequency of Tregs (173). However, dosage may significantly affect the outcome, as low-dose versus high-dose IL-2 therapy differentially promotes Tregs and Tconvs, respectively (174). In fact, in contrast to low-dose IL-2, treatment of NOD mice with high-dose IL-2 accelerated progression of diabetes (76, 175). Thus, approaches aimed at boosting Tregs may need to combine IL-2 treatment with therapies targeting pathogenic Teffs. The mTOR inhibitor rapamycin selectively inhibits the proliferation of Th1 and Th17 cells while enhancing Treg survival (176–178). Treatment of patients with new-onset TID with rapamycin plus low-dose IL-2 resulted in a transient increase in the frequency of Tregs and stable restoration of IL-2 signaling that persisted long after treatment was discontinued (179). However, the combination therapy also transiently impaired β cell function and dramatically increased numbers of natural killer cells and eosinophils, which might have adversely impacted pancreatic islet cells. Thus, IL-2 therapy alters a complex cellular network and additional studies will be necessary to design treatments specifically targeting Tregs. Improved knowledge of the structural properties of IL-2 binding to its receptors on different cell types and advances in protein bioengineering may help solve this conundrum via generation of mutated forms of IL-2 that selectively signal in Tregs (180, 181).

**Cellular therapy to restore tolerance.** The favorable therapeutic profile of Tregs has led to strong interest in Treg-based cellular therapy in transplantation and autoimmune diseases (182). Adoptive transfer of Tregs suppressed inflammation and disease in EAE, NOD mice, and mouse models of IBD and SLE (59, 60, 183–185). Of note, Tregs expanded in vitro were more efficient at controlling autoimmune responses than their freshly isolated counterparts (184, 186). We have developed a clinically relevant procedure for generating large numbers of CD4+CD127+/-CD25+ Tregs without the need for additional selective agents (71, 72, 187) and used a current good manufacturing practices–compliant method in a phase I clinical trial of Treg administration in TID patients. We found that autologous ex vivo–expanded Tregs were well tolerated and long lived, and that average C-peptide levels remained stable for up to two years after treatment (ClinicalTrials.gov identifier NCT01210664), consistent with the one-year follow-up data of a small phase I study in children with TID (188). Future clinical applications may involve the use of genetically modified Tregs that express genes that promote their survival, stability, trafficking, or suppressive function. In models of diabetes, tissue antigen–specific Tregs are more efficient than polyclonal cells at suppressing autoimmunity (184, 189). However, selective expansion of autoantigen–specific Tregs is challenging because of their low precursor frequency and the uncertainty of which antigens to target in most diseases. Redirecting polyclonal Tregs by engineering expression of antigen-specific receptors may help bridge this gap and may also circumvent Treg inefficiencies related to expression of inadequate TCR repertoires, as we and others have recently shown (190–193). These findings support the notion that polyclonal human Tregs could be engineered to express TCRs specific for self antigens in the target tissue in order to improve the efficacy of Treg therapy at protecting this tissue (15). Moreover, this approach could be combined with in vitro or in vivo treatments aimed at correcting other Treg defects, such as the long-term restoration of IL-2 signaling defects by low-dose IL-2 therapy in vivo (179).

Other appealing approaches in cellular therapy involve the use of tissues generated from human pluripotent stem cells (hPSCs). Given that thymic transplantation offers the potential to establish donor-specific tolerance, hPSCs could be differentiated into both one organ for transplantation (e.g., pancreatic β cells for TID) and a second organ (e.g., the thymus) to ensure graft-specific tolerance without the need for sustained immuno-
suppression (194, 195). Coupled with such regenerative strategies, advances in genetic modification of stem cells and iPSCs may soon allow us to engineer thymus or correct defects in order to modulate and enforce tolerance. Although not ready for prime time, these therapeutic strategies have tremendous potential, considering that human embryonic stem cells have recently been used to generate both thymic epithelial progenitors (196, 197) and islet-like structures (198, 199) that recapitulate the function of their adult differentiated counterparts upon transplantation in mice or humanized models.

Conclusion
Despite the wide swath of redundant mechanisms that control central and peripheral tolerance, the high incidence of autoimmune diseases and difficulty restoring tolerance in humans reflect the equally powerful mechanisms that ensure effective immune responses against pathogens. Thus, multiple pathways will likely need to be targeted to restore tolerance to self antigens without compromising overall immunity (Figure 3). Tremendous progress has been made in our understanding of the pathways that control autoimmunity and defects associated with distinct autoimmune diseases, leading to many novel therapeutic approaches targeting individual pathways. Combination therapies have been introduced in clinical trials with mixed results, which emphasizes that they could be more efficacious; however, combination treatments might raise new safety challenges as well (200). In the future, customized therapies and combination therapies should be informed not only by pathways found to be important in each autoimmune disease but also by the genetic and environmental influences in each patient, as certain treatments may be predicted to have greater efficacy depending on individual genetic susceptibility and immunological history. This increased level of granularity will undoubtedly reveal additional complexity in the molecular and cellular interactions underlying autoimmunity, but it is also bound to result in improved control of autoimmune diseases in individual patients in the new era of precision medicine.

Acknowledgments
We thank members of the Bluestone and Anderson labs for contributions to the science that drove much of the commentary in this Review. This work was funded by the National Institute of Allergy and Infectious Diseases (grants R01AI046643 and R01AI097457); the National Institute of Diabetes, Digestive and Kidney Diseases (grant R01DK101622); the Juvenile Diabetes Research Foundation (grants 17-2011-661 and 17-2013-513); the JDRF Collaborative Center for Treg Biology; and the California Institute for Regeneration Medicine (grant RB5-07262).

Address correspondence to: Jeffrey Bluestone, Diabetes Center, University of California San Francisco, HSW 1112 Box 0540, 513 Parnassus Ave., San Francisco, California 94143-0540, USA.

Phone: 415.514.0417; E-mail: jeff.bluestone@uwf.edu.


